Emerging roles of hematopoietic cells in the pathobiology of diabetic complications

Trends in Endocrinology and Metabolism

Volumn 25, Issue 4, 2014, Pages 178-187

  Kojima, Hideto ^a,b   Kim, Jongoh ^a   Chan, Lawrence ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Bone marrow; Complications; Diabetes mellitus; Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; Hematopoietic cells

Indexed keywords

BONE MARROW; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; ENDOTHELIAL PROGENITOR CELL; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYPERGLYCEMIA; LEUKOSTASIS; MICROANGIOPATHY; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; STEM CELL NICHE; ANIMAL; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BONE MARROW; DIABETES COMPLICATIONS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; HYPERGLYCEMIA;

EID: 84897069138     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.01.002     Document Type: Review

References (97)

1. Brownlee M. The pathobiology of diabetic complications a unifying mechanism. Diabetes 2005, 54:1615-1625.
2. Manigrasso M.B., et al. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol. Metab. 2014, 25:15-22.
3. Rask-Madsen C., King G.L. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013, 17:20-33.
4. Fadini G.P., et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2005, 45:1449-1457.
5. Fadini G.P., et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006, 49:3075-3084.
6. Fadini G.P., et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010, 33:1097-1102.
7. Oikawa A., et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler. Thromb. Vasc. Biol. 2010, 30:498-508.
8. Spinetti G., et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ. Res. 2013, 112:510-522.
9. Ferraro F., et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci. Transl. Med. 2011, 3:104ra101.
10. Orlandi A., et al. Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice. Basic Res. Cardiol. 2010, 105:703-712.
11. Hazra S., et al. Long-term type 1 diabetes influences haematopoietic stem cells by reducing vascular repair potential and increasing inflammatory monocyte generation in a murine model. Diabetologia 2013, 56:644-653.
12. Min D., et al. Alterations in monocyte CD16 in association with diabetes complications. Mediators Inflamm. 2012, 2012:649083.
13. Fadini G.P., et al. An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia 2013, 56:1856-1866.
14. Fadini G.P., et al. Monocyte-macrophage polarization balance in pre-diabetic individuals. Acta Diabetol. 2013, 50:977-982.
15. Navarro-González J.F., et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 2011, 7:327-340.
16. Hammes H-P., et al. Diabetic retinopathy: targeting vasoregression. Diabetes 2011, 60:9-16.
17. Adamis A.P., Berman A.J. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 2008, 30:65-84.
18. Kern T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 2007:95103.
19. Chan L., et al. Pathogenesis of diabetic neuropathy: bad to the bone. Ann. N. Y. Acad. Sci. 2011, 1240:70-76.
20. Fadini G.P. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia 2014, 57:4-15.
21. Fadini G.P., Avogaro A. It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications. Exp. Diabetes Res. 2012, 2012:742976.
22. Menegazzo L., et al. Endothelial progenitor cells in diabetes mellitus. Biofactors 2012, 38:194-202.
23. Asahara T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-966.
24. Urbich C., Dimmeler S. Endothelial progenitor cells characterization and role in vascular biology. Circ. Res. 2004, 95:343-353.
25. Hill J.M., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003, 348:593-600.
26. Asahara T., et al. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011, 29:1650-1655.
27. Hagensen M.K., et al. Circulating endothelial progenitor cells do not contribute to regeneration of endothelium after murine arterial injury. Cardiovasc. Res. 2012, 93:223-231.
28. Yoder M.C. Human endothelial progenitor cells. Cold Spring Harb. Perspect. Med. 2012, 2:a006692.
29. Loomans C.J.M., et al. Endothelial progenitor cell dysfunction a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004, 53:195-199.
30. Tepper O.M., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
31. Sibal L., et al. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 2009, 52:1464-1473.
32. Egan C.G., et al. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 2008, 51:1296-1305.
33. Avogaro A., et al. Endothelial dysfunction in diabetes the role of reparatory mechanisms. Diabetes Care 2011, 34:S285-S290.
34. Fadini G.P., et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013, 36:943-949.
35. Fadini G.P., Avogaro A. Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease: a meta-regression analysis. Int. J. Cardiol. 2013, 168:892-897.
36. Gallagher K.A., et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α. J. Clin. Invest. 2007, 117:1249-1259.
37. Busik J.V., et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J. Exp. Med. 2009, 206:2897-2906.
38. Nagareddy P.R., et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013, 17:695-708.
39. Oh S-H., et al. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. Lab. Invest. 2004, 84:607-617.
40. Terashima T., et al. Bone marrow expression of poly (ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion. FASEB J. 2012, 26:295-308.
41. González F., et al. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome. J. Endocrinol. 2006, 188:521-529.
42. Kojima H., et al. Extrapancreatic insulin-producing cells in multiple organs in diabetes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2458-2463.
43. Terashima T., et al. The fusion of bone-marrow-derived proinsulin-expressing cells with nerve cells underlies diabetic neuropathy. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12525-12530.
44. Fujimiya M., et al. Fusion of proinsulin-producing bone marrow-derived cells with hepatocytes in diabetes. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4030-4035.
45. Yamashita T., et al. Fusion of bone marrow-derived cells with renal tubules contributes to renal dysfunction in diabetic nephropathy. FASEB J. 2012, 26:1559-1568.
46. Chan L., et al. Chronic diabetic complications: the body's adaptive response to hyperglycemia gone awry?. Trans. Am. Clin. Climatol. Assoc. 2006, 117:341-352.
47. Shantsila E., et al. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol. 2007, 49:741-752.
48. Kanwar Y.S., et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. 2011, 6:395-423.
49. Guo J-K., Cantley L.G. Cellular maintenance and repair of the kidney. Annu. Rev. Physiol. 2010, 72:357-376.
50. Zheng F., et al. Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes 2004, 53:2420-2427.
51. Ezquer F., et al. Endovenous administration of bone marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol. Blood Marrow Transplant. 2009, 15:1354-1365.
52. Wang Y., Harris C.H. Macrophages in renal disease. J. Am. Soc. Nephrol. 2011, 22:21-27.
53. Sassy-Prigent C., et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000, 49:466-475.
54. Coimbra T.M., et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 2000, 57:167-182.
55. Chow F., et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004, 65:116-128.
56. Young B.A., et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int. 1995, 47:935-944.
57. Utimura R., et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes1. Kidney Int. 2003, 63:209-216.
58. Okada S., et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52:2586-2593.
59. Chow F.Y., et al. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J. Am. Soc. Nephrol. 2005, 16:1711-1722.
60. Chow F.Y., et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006, 69:73-80.
61. Chow F.Y., et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
62. Awad A.S., et al. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am. J. Physiol. Renal Physiol. 2011, 301:F1358-F1366.
63. Sayyed S.G., et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int. 2011, 80:68-78.
64. Seok S.J., et al. Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol. Dial. Transplant. 2013, 28:1700-1710.
65. Lim A.K.H., et al. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009, 52:1669-1679.
66. Zheng D., et al. Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus. Nephron Exp. Nephrol. 2011, 118:e87-e99.
67. Furuta T., et al. The role of macrophages in diabetic glomerulosclerosis. Am. J. Kidney Dis. 1993, 21:480-485.
68. Bohle A., et al. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis. Pathol. Res. Pract. 1991, 187:251-259.
69. Nguyen D., et al. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006, 11:226-231.
70. Simó R., et al. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br. J. Ophthalmol. 2012, 96:1285-1290.
71. Anand-Apte B. Dysfunction of circulating endothelial progenitor cells in diabetic retinopathy. Studies on Retinal and Choroidal Disorders 2012, 517-528. Springer. R.D. Stratton (Ed.).
72. Schröder S., et al. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am. J. Pathol. 1991, 139:81-100.
73. Miyamoto K., et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:10836-10841.
74. Joussen A.M., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18:1450-1452.
75. + bone marrow-derived monocytes are the major leukocyte subset responsible for retinal capillary leukostasis in experimental diabetes in mouse and express high levels of CCR5 in the circulation. Am. J. Pathol. 2012, 181:719-727.
76. Li G., et al. Marrow-derived cells regulate the development of early diabetic retinopathy and tactile allodynia in mice. Diabetes 2012, 61:3294-3303.
77. Talahalli R., et al. Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. J. Leukoc. Biol. 2013, 93:135-143.
78. McLeod D.S., et al. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am. J. Pathol. 1995, 147:642-653.
79. Dong N., et al. Upregulation of retinal neuronal MCP-1 in the rodent model of diabetic retinopathy and its function in vitro. Invest. Ophthalmol. Vis. Sci. 2012, 53:7567-7575.
80. Vincent A.M., et al. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat. Rev. Neruol. 2011, 7:573-583.
81. Han J.W., et al. Cell therapy for diabetic neuropathy using adult stem or progenitor cells. Diabetes Metab. J. 2013, 37:91-105.
82. Nukada H., et al. Increased susceptibility to ischemia and macrophage activation in STZ-diabetic rat nerve. Brain Res. 2011, 1373:172-182.
83. Toth C., et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008, 57:1002-1017.
84. Juranek J.K., et al. RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes 2013, 62:931-943.
85. Jung H., et al. Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J. Neurosci. 2009, 29:8051-8062.
86. Kalliomäki J., et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2)-antagonist in posttraumatic neuralgia. Pain 2013, 154:761-767.
87. Kalliomäki J., et al. Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy. Scand. J. Pain 2013, 4:77-83.
88. Balasanthiran A., et al. Hyperglycaemia in the acute care setting. Clin. Med. 2012, 12:272-275.
89. El-Osta A., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 2008, 205:2409-2417.
90. Papanas N., et al. Neuropathy in prediabetes: does the clock start ticking early?. Nat. Rev. Endocrinol. 2011, 7:682-690.
91. Narendran P., et al. Proinsulin is encoded by an RNA splice variant in human blood myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16430-16435.
92. Yamakawa I., et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E844-E852.
93. Katayama Y., et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006, 124:407-421.
94. Méndez-Ferrer S., et al. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008, 452:442-447.
95. Méndez-Ferrer S., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
96. Kojima H., et al. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat. Med. 2003, 9:596-603.
97. Yechoor V., et al. Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes. Dev. Cell 2009, 16:358-373.